Method for monitoring and controlling drug resistance of gastrointestinal stromal tumor patient to imatinib/sunitinib through ddPCR technology

Abstract

The invention discloses a method for monitoring and controlling drug resistance of a gastrointestinal stromal tumor patient to imatinib / sunitinib through ddPCR technology. The method comprises: extracting DNA from peripheral plasma or serum of a gastrointestinal stromal tumor patient, detecting a mutation situation of a drug-resistant mutation site T670I, D816V, or D842V of C-kit or PDGFR[alpha] in the DNA through ddPCR technology, and judging if the patient produces drug resistance according to the mutation situation.

Description

technical field [0001] The present invention relates to the fields of medicine and biotechnology, in particular to a molecular detection technology that can be used to guide tumor treatment, especially for highly sensitive detection of C-kit gene (T670I, D816V) / PDGFRα gene (D842V) mutations and Its application in the monitoring of imatinib / sunitinib resistance in patients with gastrointestinal stromal tumors. Background technique [0002] Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract, and their biological behaviors are complex and changeable. GIST is not sensitive to traditional radiotherapy and chemotherapy, and previous surgery is the only effective treatment for GIST. In recent years, molecular targeting research has made great progress in gastrointestinal stromal tumors. The tyrosine kinase inhibitor imatinib (imatinib) can significantly improve the clinical prognosis of patients with advanced GIST, and has mild sid...

AI Technical Summary

Problems solved by technology

[0007] However, due to the extremely small amount of plasma cell-free DNA in the blood and the interference of a large amount of blood-derived DNA, it is still difficult to accurately isolate and purify DNA with high-efficiency DNA enrichment methods and high-sensitivity detection methods (such as sequencing, digital PCR). and reliably detect the specific types and sequences of tumor-associated cell-free DNA

For example, it has been reported in the literature that although the average content of circulating cell-free DNA (4771ng / ml) in patients with colorectal cancer is significantly different from that in healthy people (0.85ng / ml), for 67 patients with carcinoembryonic antigen (CEA) Only 47% of the test results are meaningful for diagnosis

[0008] Therefore, although the detection technology based on free blood DNA is the focus of research and development, there is still a lack of satisfactory mutant DNA detection technology in this field that can truly meet the clinical needs of high sensitivity, high accuracy and high reliability.

Images